CRISPR Therapeutics AG Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	4.1	-	-	-	1.2	914.96
Revenue Growth (YoY)	-89.11%	-	-	-	-99.87%	127154.94%
Gross Profit	4.1	-	-	-	1.2	914.96
Selling, General & Admin	71.43	-	-	-	102.46	99.69
Research & Development	377.15	-	-	-	461.65	340.57
Other Operating Expenses	201.92	-	-	-	110.25	101.18
Total Operating Expenses	650.5	0	0	0	674.36	541.44
Operating Income	-646.4	-	-	-	-673.16	373.53
Total Non-Operating Income (Expense)	89.38	86.61	103.9	71.82	22.66	6
Pretax Income	-557.01	86.61	103.9	71.82	-650.5	379.53
Provision for Income Taxes	3.36	-	-	-	-0.33	1.87
Net Income	-568.53	86.61	103.9	71.82	-650.18	377.66
Net Income to Common	-568.53	86.61	103.9	71.82	-650.18	377.66
Net Income Growth	-	-16.65%	44.68%	-	-	-
Shares Outstanding (Basic)	92	90	84	79	78	76
Shares Outstanding (Diluted)	92	90	84	79	78	80
Shares Change (YoY)	8.24%	6.60%	6.49%	1.90%	-3.29%	21.90%
EPS (Basic)	-6.22	-6.47	-4.34	-1.94	-8.36	4.97
EPS (Diluted)	-6.22	-6.47	-4.34	-1.94	-8.36	4.70
Shares Outstanding	96.39	95.89	85.74	80.04	78.51	76.99
Free Cash Flow	-401.18	-345.93	-144.68	-269.85	-532.93	457.27
Free Cash Flow Per Share	-4.34	-3.85	-1.71	-3.41	-6.85	5.69
Gross Margin	100.00%	-	-	-	100.00%	100.00%
Operating Margin	-15754.20%	-	-	-	-56190.40%	40.82%
Profit Margin	-13856.50%	-	-	-	-54271.70%	41.28%
FCF Margin	-9777.63%	-	-	-	-44484.90%	49.98%
EBITDA	-627.33	19.48	19.26	19.84	-648.99	391.48
EBITDA Margin	-15289.60%	-	-	-	-54172.70%	42.79%
EBIT	-646.4	-	-	-	-673.16	373.53
EBIT Margin	-15754.20%	-	-	-	-56190.40%	40.82%
Effective Tax Rate	-0.60%	0.00%	0.00%	0.00%	0.05%	0.49%

Updated May 4, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q